# EDGAR Filing Document

**Accession Number:** 0001715925
**File Stem:** 0000950170-25-101136
**Filing Date:** 2025-8
**Character Count:** 3597
**Document Hash:** 6d6843381d7e776b5eb67f19c09e3a2c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-101136.hdr.sgml**: 20250801

**ACCESSION NUMBER**: 0000950170-25-101136

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250801

**FILED AS OF DATE**: 20250801

**DATE AS OF CHANGE**: 20250801

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ImmunoPrecise Antibodies Ltd.
- **CENTRAL INDEX KEY:** 0001715925
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39530
- **FILM NUMBER:** 251174207

**BUSINESS ADDRESS:**
- **STREET 1:** INDUSTRIOUS, 823 CONGRESS AVE, SUITE 300
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701
- **BUSINESS PHONE:** 6048060626

**MAIL ADDRESS:**
- **STREET 1:** INDUSTRIOUS, 823 CONGRESS AVE, SUITE 300
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**Form 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

For the month of **<u>August, 2025</u>**.

Commission File Number: **<u>001-39530</u>**

 **<u>ImmunoPrecise Antibodies Ltd.</u>** 

**Industrious 823 Congress Ave Suite 300 Austin, Texas 78701**

(Address of principal executive office)

------

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit**<br>| &nbsp;&nbsp;&nbsp;**Description**<br>|
| &nbsp;&nbsp;99.1<br>| [<u>Notice of Meeting and Record Date dated August 1, 2025</u>](ipa-ex99_1.htm) |

---

------

**<u>SIGNATURES</u>** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **IMMUNOPRECISE ANTIBODIES LTD.** | **IMMUNOPRECISE ANTIBODIES LTD.** |
| Date: August 1, 2025 |  |  |
|  | By: | /s/ Jennifer Bath<br>|
|  | Name: | Jennifer Bath |
|  | Title: | President and Chief Executive Officer |

---

------

## Exhibit 99.1

ImmunoPrecise Antibodies Ltd.

3204-4464 Markham Street

Victoria, BC, Canada V8Z 7X8

PH: +1 (250) 483-0308

**Website: www.ipatherapeutics.com Email: info@ipatherapeutics.com**

---

| |
|:---|
| Date: August 1, 2025<br>|
| To: All Canadian Securities Regulatory Authorities<br> NASDAQ Exchange |
| **Subject: IMMUNOPRECISE ANTIBODIES LTD.** |
| Dear Sir/Madam:<br>We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer:  |
| Meeting Type : Annual General Meeting<br>Record Date for Notice of Meeting : August 27, 2025<br>Record Date for Voting (if applicable) : August 27, 2025<br>Beneficial Ownership Determination Date: August 27, 2025<br>Meeting Date : October 9, 2025<br>Meeting Location (if available) : Virtual Meeting<br>Issuer sending proxy related materials directly to NOBO: No<br>Issuer paying for delivery to OBO: No<br>**Notice and Access (NAA) Requirements:**<br>&nbsp;&nbsp;&nbsp;&nbsp;NAA for Beneficial Holders No<br>&nbsp;&nbsp;&nbsp;&nbsp;NAA for Registered Holders No |
| <br>**Voting Security Details:** |
| Description CUSIP Number ISIN<br>COMMON 45257F200 CA45257F2008 |
| <br>Sincerely, <br>**IMMUNOPRECISE ANTIBODIES LTD.** |

---

------